Acticor Biotech SAS

As of December 31, 2023, Acticor Biotech SAS has 13.12M shares outstanding.

These figures are as of December 31, 2023.

As of December 31, 2023, Acticor Biotech SAS maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -110.56, indicating conservative leverage, while an interest coverage ratio of -9.70 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2023. Return on assets (ROA) is negative at -164.53, reflecting losses generated across the asset base.

As of the close on January 6, 2025, Acticor Biotech SAS's stock has declined approximately 91.61% over the past 52 weeks. The 50-day moving average sits at 0.32, while the 200-day moving average is 0.81.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -37.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -29.60, meaning Acticor Biotech SAS raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2023, Acticor Biotech SAS has an Altman Z-Score of -10.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.